Yüklüyor......
Engineering better chimeric antigen receptor T cells
CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relap...
Kaydedildi:
| Yayımlandı: | Exp Hematol Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7709221/ https://ncbi.nlm.nih.gov/pubmed/33292660 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00190-2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|